Tape measure cost to the health system has advanced to $10B per year. The tape measure does not detect subclinical and only confirms that you have got lymphedema & for the majority it is for the rest of your life.
SOZO detects 90+% of cases early (subclinical level where treatment does stop BCRL progress) estimated cost $2B to detect per year all for all cancer related lymphedema. Other time the overall cost will reduce as existing BCRL patients depart, and the addition of new patients is significantly reduced.
2 years' worth of cash, revenue is increasing every quarter and cash burn has stabilised.
IPD has tested itself with a SOZO for HF and came back negative.
Accumulate Acclivity
IPD Price at posting:
2.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)